2012
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)
Ruddy KJ, Pitcher BN, Archer LE, Cohen HJ, Winer EP, Hudis CA, Muss HB, Partridge AH. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Annals Of Oncology 2012, 23: 3075-3081. PMID: 22767584, PMCID: PMC3501229, DOI: 10.1093/annonc/mds133.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancerBreast cancerMedication calendarOral cyclophosphamideStandard chemotherapyStage I-IIIB breast cancerSelf-reported adherenceCase report formsToxic effectsAdjuvant chemotherapyCALGB 49907Febrile neutropeniaOral CMFNode negativityOlder patientsStandard therapyMedian ageSuperior tolerabilityRandomized trialsCyclophosphamide dosesAverage adherenceOlder womenCyclophosphamideChemotherapyConsecutive days
2011
Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840
Lichtman S, Hurria A, Cirrincione C, Seidman A, Winer E, Hudis C, Cohen H, Muss H, B F. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Annals Of Oncology 2011, 23: 632-638. PMID: 21693770, PMCID: PMC3331731, DOI: 10.1093/annonc/mdr297.Peer-Reviewed Original ResearchConceptsProgression-free survivalGood performance statusFirst-line therapyMetastatic breast cancerOverall survivalPerformance statusBreast cancerOlder womenLeukemia Group B StudySecond-line therapyImproved overall survivalDoses of paclitaxelEstrogen receptor-positive statusTolerability of paclitaxelToxic effectsBilirubin elevationPaclitaxel efficacyWeekly paclitaxelOlder patientsMetastatic sitesTumor responseSimilar efficacyPositive statusSpecific toxic effectsPatients
2001
Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer
Partridge A, Burstein H, Winer E. Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer. JNCI Monographs 2001, 2001: 135-142. PMID: 11773307, DOI: 10.1093/oxfordjournals.jncimonographs.a003451.Peer-Reviewed Original ResearchConceptsLong-term side effectsSide effectsChemohormonal therapyAdjuvant chemotherapyShort-term side effectsEarly-stage breast cancerSide effect profileDuration of treatmentLong-term toxicityAdjuvant regimenLate complicationsEffect profileTherapy regimensBreast cancerChemotherapySpecific agentsTherapyToxic effectsPossible risksTreatmentPotential benefitsConsiderable variabilityRegimenRegimensComplications
1992
High-Dose Oral Tamoxifen, a Potential Multidrug-Resistance-Reversal Agent: Phase I Trial in Combination With Vinblastine
Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL. High-Dose Oral Tamoxifen, a Potential Multidrug-Resistance-Reversal Agent: Phase I Trial in Combination With Vinblastine. Journal Of The National Cancer Institute 1992, 84: 1811-1816. PMID: 1359155, DOI: 10.1093/jnci/84.23.1811.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntineoplastic Combined Chemotherapy ProtocolsATP Binding Cassette Transporter, Subfamily B, Member 1Drug Administration ScheduleDrug ResistanceFemaleHumansInfusions, IntravenousMaleMembrane GlycoproteinsMiddle AgedNeoplasm ProteinsNeoplasmsTamoxifenVinblastineConceptsLoading doseN-desmethyltamoxifenOral tamoxifenContinuous infusionPlasma concentrationsHigh-dose oral tamoxifenDose-limiting toxic effectPhase I clinical trialAdvanced epithelial tumorsHigh-dose tamoxifenTriphenylethylene antiestrogen tamoxifenPhase II trialDose-limiting toxicityPhase I trialDoses of tamoxifenStart of treatmentP-glycoprotein functionToxicity of vinblastineAnti-neoplastic agentsToxic effectsMetabolite N-desmethyltamoxifenIntracellular concentrationAsymptomatic prolongationStarting doseII trial